CHARACTERISTICS OF [H-3] GBR-12935 BINDING IN THE HUMAN AND RAT FRONTAL-CORTEX

Binding characteristics of the selective dopamine uptake inhibitor [H-3]GBR 12935 have been described for the striatum but not for the frontal cortex. We have developed assay conditions for quantifying [H-3]GBR 12935 binding in the frontal cortex. In both the rat and human frontal cortex, the assay required four times more tissue (8 mg/ml) than in the striatum (2 mg/ml). [H-3]GBR 12935 binding in the frontal is complex, as it involves multiple binding sites. The high-affinity binding site is sodium dependent and is inhibited by sodium. In human but not in rat frontal cortex, addition of K+ reversed the sodium inhibition. The pharmacological profile of the high-affinity [H-3]GBR 12935 binding site is consistent with that of the dopamine transporter, because drugs with the most selective dopamine reuptake blocking activities are the most potent displacers of [H-3]GBR 12935 binding. There is a positive correlation between the rat and human inhibitory constants, a finding indicating that there are similar pharmacological profiles across at least these two species. Rats with a 6-hydroxydopamine lesion had a 47% decrease in number of [H-3]GBR 12935 binding sites, a result indicating that at least a portion of these sites had been on presynaptic dopamine terminals.